PWMG
CHRS icon

Prestige Wealth Management Group’s Coherus Oncology CHRS Stock Holding History

Prestige Wealth Management Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-129
Closed -$3K – 583
2019
Q3 		$3K Buy
+129
New +$2.58K ﹤0.01% 449

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Prestige Wealth Management Group's CHRS Position: Q4 2019 in Review

Prestige Wealth Management Group sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 129 shares — an estimated $3K sold.

Prestige Wealth Management Group first reported a position in CHRS in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

  • Prestige Wealth Management Group reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
  • Prestige Wealth Management Group sold 129 Coherus Oncology shares in Q4 2019, an estimated $3K.
  • Prestige Wealth Management Group first reported a position in Coherus Oncology in Q3 2019 and held it in 1 quarter.
  • Prestige Wealth Management Group's Coherus Oncology position peaked at $3K in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Prestige Wealth Management Group's 13F filing for Q4 2019, filed 28 Jan 2020.